Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corporate Compliance Programs Are Often Inadequate To Avoid Foreign Corruption Investigations, DoJ Official Says

Executive Summary

Pharmaceutical companies have spent a vast amount of resources bolstering their compliance programs in the wake of government investigations of their domestic marketing practices. But their procedures may be insufficient to detect corruption and bribery abroad
Advertisement

Related Content

J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe
SEC, DoJ Beef Up Investigation of Corporate Bribery & Corruption Overseas
SEC, DoJ Beef Up Investigation of Corporate Bribery & Corruption Overseas

Topics

Advertisement
UsernamePublicRestriction

Register

PS052248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel